Iressa Coverage Under Part D Should Be Consistent With On-Label Use – WLF
Executive Summary
AstraZeneca's oncology drug Iressa should be reimbursed under Medicare Part D for lung cancer patients who are already benefiting from it, the Washington Legal Foundation urges in Aug. 19 comments to the Centers for Medicare & Medicaid Services